Skip to main content
SpringerLink
Log in

Treatment of Advanced-Stage Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 998 Accesses

Abstract

Before the introduction of combination chemotherapy, more than 95% of patients with advanced classical Hodgkin lymphoma (cHL) succumbed to their disease within 5 years. Thus, remission rates in excess of 50% achieved with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) were a major breakthrough in oncology when first seen over 40 years ago. Systematic searches for more effective regimens have replaced MOPP by ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone). With today’s high survival rates exceeding 90%, it is important to balance cure against short- and long-term adverse effects of treatment. Consequently, response-adapted approaches, mainly using 18-fluorodeoxyglucose-positron emission tomography-computer tomography (FDG-PET-CT), have been introduced as the standard of care allowing for individualized tailored treatment. After many years without new drugs, research has been energized by the possible introduction of novel agents, that is, the antibody-drug conjugate brentuximab vedotin and programmed death receptor-1 inhibitory antibodies, which are increasingly being tested as components of initial therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaplan HS (1972) Hodgkin’s disease. Harvard University Press, Cambridge, MA. 452 p

    Google Scholar 

  2. Devita VT Jr, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73(6):881–895

    Article  PubMed  Google Scholar 

  3. DeVita VT Jr, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH 3rd et al (1980) Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92(5):587–595

    Article  PubMed  Google Scholar 

  4. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36(1):252–259

    Article  CAS  PubMed  Google Scholar 

  5. Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med 104(6):739–746

    Article  CAS  PubMed  Google Scholar 

  6. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5(1):27–37

    Article  CAS  PubMed  Google Scholar 

  7. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21(4):607–614

    Article  CAS  PubMed  Google Scholar 

  8. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L et al (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 14(5):1421–1430

    Article  CAS  PubMed  Google Scholar 

  9. Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM et al (1997) Treatment of advanced Hodgkin’s disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15(4):1638–1645

    Article  CAS  PubMed  Google Scholar 

  10. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. New Engl J Med 327(21):1478–1484

    Article  CAS  PubMed  Google Scholar 

  11. Geel JA, Chirwa TC, Rowe B, Eyal KC, Omar F, Stones DK et al (2017) Treatment outcomes of children with Hodgkin lymphoma between 2000 and 2010: First report by the South African Children’s Cancer Study Group. Pediatr Blood Cancer 64:10

    Article  CAS  Google Scholar 

  12. Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z et al (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leukemia Lymphoma 49(8):1486–1493

    Article  CAS  PubMed  Google Scholar 

  13. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM et al (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Brit J Haematol 161(1):76–86

    Article  CAS  Google Scholar 

  14. Canellos GP, Niedzwiecki D (2002) Long-term follow-up of Hodgkin’s disease trial. New Engl J Med 346(18):1417–1418

    Article  PubMed  Google Scholar 

  15. Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R et al (2004) Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol 15(2):276–282

    Article  CAS  PubMed  Google Scholar 

  16. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23(36):9198–9207

    Article  CAS  PubMed  Google Scholar 

  17. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS et al (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23(36):9208–9218

    Article  CAS  PubMed  Google Scholar 

  18. Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP et al (2002) ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 20(13):2988–2994

    Article  CAS  PubMed  Google Scholar 

  19. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW et al (2009) Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 27(32):5390–5396

    Article  PubMed  Google Scholar 

  20. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. New Engl J Med 348(24):2386–2395

    Article  CAS  PubMed  Google Scholar 

  21. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD et al (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29(32):4234–4242

    Article  CAS  PubMed  Google Scholar 

  22. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799

    Article  CAS  PubMed  Google Scholar 

  23. Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 7(Suppl 4):95–98

    Article  PubMed  Google Scholar 

  24. Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Ruffer U et al (1998) Moderate dose escalation for advanced stage Hodgkin’s disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s Lymphoma Study Group. Blood 92(12):4560–4567

    Article  CAS  PubMed  Google Scholar 

  25. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig W-D et al (2009) Escalated-Dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554

    Article  PubMed  Google Scholar 

  26. von Tresckow B, Kreissl S, Goergen H, Brockelmann PJ, Pabst T, Fridrik M et al (2018) Intensive treatment strategies in advanced-stage Hodgkin’s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol 5(10):e462–ee73

    Article  Google Scholar 

  27. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10):3989–3994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V et al (2013) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31(2):231–239

    Article  CAS  PubMed  Google Scholar 

  29. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A et al (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 27(5):805–811

    Article  PubMed  Google Scholar 

  30. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V et al (2011) ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. New Engl J Med 365(3):203–212

    Article  CAS  PubMed  Google Scholar 

  31. Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O et al (2016) Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in stage III to IV, International prognostic score >/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol 34(17):2028–2036

    Article  CAS  PubMed  Google Scholar 

  32. Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M et al (2014) ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/= 4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25(8):1622–1628

    Article  CAS  PubMed  Google Scholar 

  33. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F et al (2016) Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 34(11):1175–1181

    Article  CAS  PubMed  Google Scholar 

  34. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A et al (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14(10):943–952

    PubMed  Google Scholar 

  35. Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B (2017) Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochr Datab Syst Rev 5:CD007941. https://doi.org/10.1002/14651858

    Article  CAS  Google Scholar 

  36. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. New Engl J Med 339(21):1506–1514

    Article  CAS  PubMed  Google Scholar 

  37. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752

    Article  CAS  PubMed  Google Scholar 

  38. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leukemia Lymphoma 50(8):1257–1260

    Article  PubMed  Google Scholar 

  39. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s Lymphoma. New Engl J Med 374(25):2419–2429

    Article  PubMed  Google Scholar 

  40. Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mule A et al (2018) Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 36(5):454–462

    Article  CAS  PubMed  Google Scholar 

  41. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA et al (2018) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390(10114):2790–2802

    Article  Google Scholar 

  42. Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M et al (2016) US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 34(17):2020–2027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 Study. J Clin Oncol 34(12):1376–1385

    Article  CAS  PubMed  Google Scholar 

  44. Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J et al (2018) Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood 132(21):2273–2279. https://doi.org/10.1182/blood-2018-05-852129

    Article  CAS  PubMed  Google Scholar 

  45. Casasnovas RO, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J et al (2019) PET-adapted treatment of patients with advanced Hodgkin lymphoma (AHL2011): final results of a randomised, multi-centre, phase 3 study. Lancet 20(2):202–215

    Article  Google Scholar 

  46. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M et al (2013) International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 54(5):683–690

    Article  CAS  PubMed  Google Scholar 

  47. Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R et al (2017) Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol 18(4):454–463

    Article  CAS  PubMed  Google Scholar 

  48. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN et al (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348–1356

    Article  CAS  PubMed  Google Scholar 

  50. Connors JM, Ansell SM, Fanale M, Park SI, Younes A (2017) Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood 130(11):1375–1377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s Lymphoma. New Eng J Med 378(4):331–344

    Article  CAS  PubMed  Google Scholar 

  52. Chen RW, Gallamini A, Connors JM, Savage KJ, Collins GP, Grigg A et al (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS). J Clin Oncol 36:abstr 7539

    Article  Google Scholar 

  53. Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J et al (2017) Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol 18(12):1680–1687

    Article  CAS  PubMed  Google Scholar 

  54. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H et al (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 34(23):2690–2697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ et al (2019) Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II checkmate 205 study. J Clin Oncol 37(23):1997–2007. https://doi.org/10.1200/JCO.19.00315. PMID: 31112476

  56. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA et al (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 16(3):818–829

    Article  CAS  PubMed  Google Scholar 

  57. Andrieu JM, Yilmaz U, Colonna P, Loeffler M, Brosteanu O, Hasenclever D (1999) MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin’s disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. J Clin Oncol 17(2):730–732

    Article  CAS  PubMed  Google Scholar 

  58. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van’t Veer MB, Lybeert ML et al (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. New Engl J Med 348(24):2396–2406

    Article  PubMed  Google Scholar 

  59. Ferme C, Mounier N, Casasnovas O, Brice P, Divine M, Sonet A et al (2006) Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 107(12):4636–4642

    Article  CAS  PubMed  Google Scholar 

  60. Kriz J, Reinartz G, Dietlein M, Kobe C, Kuhnert G, Haverkamp H et al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol 92(1):46–53

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and National Resource Centre for Late Effects After Cancer Therapy, Oslo University Hospital, Oslo, Norway

    Alexander Fosså

  2. KG Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway

    Alexander Fosså

  3. Department of Haematology, University Hospital F. Mitterrand and INSERM1231, Dijon, France

    René-Olivier Casasnovas

  4. Cancer Research UK Centre, University of Southampton, Southampton, UK

    Peter W. M. Johnson

Authors
  1. Alexander Fosså
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. René-Olivier Casasnovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter W. M. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter W. M. Johnson .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University Hospital Cologne, Köln, Nordrhein-Westfalen, Germany

    Andreas Engert

  2. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fosså, A., Casasnovas, RO., Johnson, P.W.M. (2020). Treatment of Advanced-Stage Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-32482-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32482-7_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32481-0

  • Online ISBN: 978-3-030-32482-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation